Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel, discuss several important presentations from the recent 2021 ASH meeting.
They focus on the new IPSS-M classification, discuss the approach to the MDS patient who is currently defined by IPSS/R as belonging to the /lower-risk group but in fact the disease behaves like a higher-risk. Finally, they discuss issues regarding the treatment of patients with HR-MDS: What can be added to hypomethylating agents? Targeted therapy with IDH1/2 inhibition and more…
